Phesgo Side Effects

Generic name: hyaluronidase / pertuzumab / trastuzumab

Medically reviewed by Drugs.com. Last updated on Nov 2, 2023.

Note: This document contains side effect information about hyaluronidase / pertuzumab / trastuzumab. Some dosage forms listed on this page may not apply to the brand name Phesgo.

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution.

Warning

Subcutaneous route (Solution)

CardiomyopathyPertuzumab/trastuzumab/hyaluronidase-zzxf administration can result in subclinical and clinical cardiac failure manifesting as congesting heart failure, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue pertuzumab/trastuzumab/hyaluronidase-zzxf for cardiomyopathy.Embryo-fetal ToxicityExposure to pertuzumab/trastuzumab/hyaluronidase-zzxf can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.Pulmonary ToxicityDiscontinue pertuzumab/trastuzumab/hyaluronidase-zzxf for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Serious side effects of Phesgo

Along with its needed effects, hyaluronidase / pertuzumab / trastuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking hyaluronidase / pertuzumab / trastuzumab:

More common

Black, tarry stools
bladder pain
bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
bloody or cloudy urine
body aches or pain
burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
chest pain or tightness
chills
cough
cracked lips
decreased urine
diarrhea
difficult, burning, or painful urination
difficult or labored breathing
difficulty swallowing
dry mouth
ear congestion
fever
frequent urge to urinate
general feeling of discomfort or illness
headache
increased thirst
irregular heartbeat
joint pain
lack or loss of strength
loss of appetite
loss of voice
lower back or side pain
mood changes
muscle pain or cramps
nausea
nosebleed
numbness or tingling in the hands, feet, or lips
pale skin
redness, swelling, pain of the skin
runny or stuffy nose
scaling of the skin on the hands and feet
seizures
shivering
sneezing
sore throat
sores, ulcers, or white spots on the lips, tongue, or inside the mouth
sweating
swelling of the hands, ankles, feet, or lower legs
trouble sleeping
unusual bleeding or bruising
unusual tiredness or weakness
vomiting

Less common

Dizziness
itching, skin rash

Rare

Chest discomfort
dilated neck veins
thickening of bronchial secretions
weight gain

Incidence not known

Agitation
bleeding gums
confusion
decreased awareness or responsiveness
depression
hostility
irritability
joint stiffness or swelling
loss of consciousness
lower back, side, or stomach pain
mood or mental changes
muscle twitching
pinpoint red spots on the skin
severe sleepiness
stomach cramps
tremor
unusual drowsiness, dullness, or feeling of sluggishness

Other side effects of Phesgo

Some side effects of hyaluronidase / pertuzumab / trastuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Belching
bleeding after defecation
bone pain
change in or loss of taste
constipation
difficulty in moving
discoloration of the nails
dry eye or skin
feeling of warmth
heartburn
increased tearing of the eye
indigestion
pain and redness of the skin at the place of radiation treatment
redness of the face, neck, arms and occasionally, upper chest
stomach discomfort or upset
thinning or loss of hair
uncomfortable swelling around the anus

For Healthcare Professionals

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution.

Hematologic

Very common (10% or more): Hemoglobin low (90%), absolute lymphocytes low (89%), leukocyte count low (82%), neutrophils low (68%), anemia (36%), platelets low (27%), neutropenia (22%)

Common (1% to 10%): Leukopenia, febrile neutropenia^[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity^[Ref]

Immunologic

Common (1% to 10%): Influenza-like illness^[Ref]

Local

Very common (10% or more): Radiation skin injury (19%), injection site reaction (15%), procedural pain (13%)

Common (1% to 10%): Injection site pain^[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (25%), arthralgia (24%), pack pain (10%)

Common (1% to 10%): Bone pain, pain in extremity, muscle spasms, musculoskeletal pain^[Ref]

Ocular

Common (1% to 10%): Lacrimation increased, dry eye^[Ref]

Metabolic

Very common (10% or more): Decreased appetite (17%), potassium low (17%), albumin low (16%), potassium high (13%), sodium low (13%), weight loss (11%)

Common (1% to 10%): Hypokalemia, glucose low, sodium high^[Ref]

Psychiatric

Very common (10% or more): Insomnia (17%)^[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection^[Ref]

Hepatic

Very common (10% or more): Alanine aminotransferase high (58%), aspartate aminotransferase high (50%)

Common (1% to 10%): Bilirubin high

Respiratory

Very common (10% or more): Cough (15%), epistaxis (12%), upper respiratory infection (11%), dyspnea (10%)

Common (1% to 10%): Rhinorrhea, nasopharyngitis, paronychia

Frequency not reported: Dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency/hypoxia, acute respiratory distress syndrome, pulmonary fibrosis, exacerbation of chemotherapy-induced neutropenia^[Ref]

Other

Very common (10% or more): Asthenia (31%), fatigue (29%), pyrexia (13%)

Common (1% to 10%): Edema peripheral, malaise

Frequency not reported: Embryofetal toxicity^[Ref]

Nervous system

Very common (10% or more): Dysgeusia (17%), headache (17%), peripheral sensory neuropathy (16%), peripheral neuropathy (12%), dizziness (13%), paresthesia (10%)^[Ref]

Renal

Very common (10% or more): Creatinine high (84%)^[Ref]

Cardiovascular

Very common (10% or more): Hot flush (12%), left ventricular cardiac dysfunction (LVEF)

Common (1% to 10%): Ejection fraction decreased

Frequency not reported: Hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, cardiac death^[Ref]

Dermatologic

Very common (10% or more): Alopecia (77%), rash (16%), dry skin (15%)

Common (1% to 10%): Nail discoloration, erythema, dermatitis, nail disorder, palmar-plantar erythrodysesthesia syndrome

Uncommon (0.1% to 1%): Pruritus^[Ref]

Gastrointestinal

Very common (10% or more): Nausea (60%), diarrhea (60%), stomatitis (25%), constipation (22%), vomiting (20%), mucosal inflammation (15%), dyspepsia (14%)

Common (1% to 10%): Hemorrhoids, abdominal pain, abdominal pain upper^[Ref]